289 related articles for article (PubMed ID: 31544361)
21. Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing.
Watanabe SN; Imai K; Nanjo H; Wakamatsu Y; Kimura Y; Katayose Y; Kamata S; Terata K; Takahashi E; Ibonai A; Yamaguchi A; Konno H; Yatsuyanagi M; Kudo C; Takashima S; Akagami Y; Nakamura R; Sato Y; Motoyama S; Nomura K; Minamiya Y
Cancer Med; 2021 Jan; 10(2):586-594. PubMed ID: 33280268
[TBL] [Abstract][Full Text] [Related]
22. Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization.
Nakagawa T; Horii R; Ito Y; Iwase T; Akiyama F
Breast Cancer; 2016 Jan; 23(1):78-84. PubMed ID: 24771412
[TBL] [Abstract][Full Text] [Related]
23. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
[TBL] [Abstract][Full Text] [Related]
26. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
28. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
29. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
30. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
Owens MA; Horten BC; Da Silva MM
Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
[TBL] [Abstract][Full Text] [Related]
31. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
32. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
33. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
34. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
35. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
36. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
[TBL] [Abstract][Full Text] [Related]
37. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
39. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer.
Alnajar H; Rosen L; Javidiparsijani S; Al-Ghamdi Y; Gattuso P
Acta Cytol; 2017; 61(2):140-144. PubMed ID: 28231581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
